Compile Data Set for Download or QSAR
Report error Found 2183 Enz. Inhib. hit(s) with Target = 'DNA damage-binding protein 1'
TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627024(US11787802, Example 30 | 2-Isopropyl-N-methyl-2...)
Affinity DataKd:  1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627056(US11787802, Example 62 | 5-(4-Acetylpiperazin-1-yl...)
Affinity DataKd: <1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627088(US11787802, Example 94 | 1-Benzyl-3-(2-oxo-2,3-dih...)
Affinity DataKd: <1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631105(US11802131, Example 32 | (4S)-N-[(3S)-2,6-Dioxopip...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627018(US11787802, Example 24 | 5-(Indoline-1-carbonyl)-1...)
Affinity DataKd:  1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627021(US11787802, Example 27 | 1-Methyl-2-oxo-N-phenyl-3...)
Affinity DataKd:  1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631102(US11802131, Example 29 | (S)-N-(2,6-Dioxopiperidin...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627126(US11787802, Example 132 | 3-Methoxy-N-(2-oxo-2,3-d...)
Affinity DataKd: <1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627064(US11787802, Example 70 | 2-(4-Aminophenyl)-N-(2-ox...)
Affinity DataKd:  1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631110(US11802131, Example 37 | N-[(3S)-2,6-Dioxo-3-piper...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627006(US11787802, Example 12 | 5-(2-(Quinolin-4-yl)-1H-i...)
Affinity DataKd:  1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627038(US11787802, Example 44 | 1-Methyl-5-phenyl-3H-imid...)
Affinity DataKd: <1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631088(US11802131, Example 15 | (1S)-N-(2,6-Dioxopiperidi...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631120(US11802131, Example 47 | (S)-N-(2,6-Dioxopiperidin...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631121(US11802131, Example 48 | (R)-N-(2,6-Dioxopiperidin...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631122(US11802131, Example 49 | (R)-N-(2,6-Dioxopiperidin...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631116(US11802131, Example 43 | (4S)-N-[(3R)-2,6-Dioxopip...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627100(US11787802, Example 106 | 2-(4-(N-Methylsulfamoyl)...)
Affinity DataKd:  1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631095(US11802131, Example 22 | (N-((R)-2,6-Dioxopiperidi...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631127(US11802131, Example 54 | US11802131, Example 56 | ...)
Affinity DataKd:  1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631128(US11802131, Example 55 | (R)-N-(2,6-Dioxopiperidin...)
Affinity DataKd: <1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627049(US11787802, Example 55 | 6-(Indoline-1-carbonyl)-1...)
Affinity DataKd: <1nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631092(US11802131, Example 19 | N-((S)-2,6-Dioxopiperidin...)
Affinity DataKd:  1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631094(US11802131, Example 21 | (S)-N-(2,6-Dioxopiperidin...)
Affinity DataKd:  1nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM511610(US11059801, Compound dBET18)
Affinity DataIC50: 1.57nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM600503(methyl 6-(2,4-dioxo-1,3,7- triazaspiro[4.4]nonan-7...)
Affinity DataKd:  2nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627050(US11787802, Example 56 | N-(1-Acetylpiperidin-4-yl...)
Affinity DataKd:  2nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627068(US11787802, Example 74 | 4-Acetamido-N-(2-oxo-2,3-...)
Affinity DataKd:  2nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631085(US11802131, Example 12 | N-(2,6-dioxo-3-piperidyl)...)
Affinity DataKd:  2nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631082(US11802131, Example 9 | N-(2,6-Dioxopiperidin-3-yl...)
Affinity DataKd:  2nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631126(US11802131, Example 53 | (R)-N-(2,6-Dioxopiperidin...)
Affinity DataKd:  2nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631100(US11802131, Example 27 | (S)-N-((S)-2,6-Dioxopiper...)
Affinity DataKd:  3nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631143(US11802131, Example 70 | (R)-N-(2,6-Dioxopiperidin...)
Affinity DataKd:  3nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631140(US11802131, Example 67 | (R)-2-(3-Acetamidophenyl)...)
Affinity DataKd:  3nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631089(US11802131, Example 16 | N-(2,6-Dioxopiperidin-3-y...)
Affinity DataKd:  3nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627078(US11787802, Example 84 | 5-[2-(1-Hydroxyethyl)benz...)
Affinity DataKd:  3nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627079(US11787802, Example 85 | 5-[2-[Hydroxy(phenyl)meth...)
Affinity DataKd:  3nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627144(US11787802, Example 150 | N-(1-((2-Oxo-2,3-dihydro...)
Affinity DataKd:  3nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627017(US11787802, Example 23 | N-(1-Acetylpiperidin-4-yl...)
Affinity DataKd:  3nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631124(US11802131, Example 51 | (R)-N-(2,6-Dioxopiperidin...)
Affinity DataKd:  3nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM600500(7-((S)-1,2,3,4- tetrahydronaphthalene-1-carbonyl)-...)
Affinity DataKd:  3nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627076(US11787802, Example 82 | Methyl 1-(2-oxo-1,3-dihyd...)
Affinity DataKd:  3nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631093(US11802131, Example 20 | N-((R)-2,6-Dioxopiperidin...)
Affinity DataKd:  3nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627077(US11787802, Example 83 | 5-(Benzimidazol-1-yl)-1,3...)
Affinity DataKd:  3nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM50544938(CHEMBL4094346 | US11059801, Compound dBET1)
Affinity DataIC50: 3.09nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM511611(US11059801, Compound dBET19)
Affinity DataIC50: 3.62nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631103(US11802131, Example 30 | (S)-N-(2,6-Dioxopiperidin...)
Affinity DataKd:  4nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM631087(US11802131, Example 14 | (1R)-N-(2,6-Dioxopiperidi...)
Affinity DataKd:  4nMAssay Description:Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in di...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/13/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627073(US11787802, Example 79 | 2-Isopropyl-N-methyl-1-(2...)
Affinity DataKd:  4nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM627099(US11787802, Example 105 | N-(2-Oxo-2,3-dihydro-1H-...)
Affinity DataKd:  4nMAssay Description:1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content2) Titration measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
US Patent

Displayed 1 to 50 (of 2183 total ) | Next | Last >>
Jump to: